Astellas Pharma Gets Positive CHMP Opinion For XTANDI In Early Prostate Cancer Treatment Setting
(RTTNews) - Astellas Pharma Inc. announced Friday the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval of XTANDI (enzalutamide) as monotherapy or in combination with androgen deprivation therapy for the treatment of adult men with high risk biochemical recurrent (BCR) non-metastatic hormone sensitive prostate cancer (nmHSPC) who are unsuitable for salvage radiotherapy.
The positive CHMP opinion is based on the results from the Phase 3 EMBARK trial.
The positive opinion will now be reviewed by the European Commission (EC), which has the authority to approve medicines in all 27 European Union (EU) member states as well as Iceland, Liechtenstein and Norway.
Astellas is also discussing the EMBARK data with other regulatory authorities to support additional license applications for XTANDI in this indication in 2024 and beyond.
Merck Says Phase 3 KEYNOTE-A39/EV-302 Trial Meets Dual Primary Endpoints
Astellas, Poseida Announce Investment To Support Poseida's Commitment To Cancer Cell Therapy
Pound Rises On Upbeat U.K. GDP Data
Deere Stock Drops On Revised FY25 Outlook, Even As Q3 Beats Street
FTSE Down Marginally As Stocks Turn In Mixed Performance
Pound Rises Against Most Majors
CAC Rises For 3rd Straight Session
